Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, B-Cell 2Cytokine Release Syndrome 2Burkitt Lymphoma 2Pancreatic Neoplasms 1Neurotoxicity Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Early Stage Triple Negative ER Low Breast Cancer 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1

Interventions

neurotropin 1haloperidol decanoate 1fludarabine phosphate 1fludarabine 1axicabtagene ciloleucel 1Temozolomide 1Tadalafil 1Surveys and Questionnaires 1Simvastatin 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Nutritional Status 1N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid 1Lorazepam 1Interleukin 1 Receptor Antagonist Protein 1Exercise Therapy 1Exercise 1Dexamethasone 1Cyclophosphamide 1Bendamustine Hydrochloride 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurotoxicity Syndromes × Interleukin 1 Receptor Antagonist Protein × 1 year × Clear all
NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Massachusetts General Hospital

Phase 2 Completed
15 enrolled 17 charts
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡